ArticleApplied biochemistry and biotechnology2026
The Effective Role of FTIR in Monitoring the Treatment of Hepatocellular Carcinoma by Using Fe2O3@Ag@Chitosan Nanocomposite Loaded with Sorafenib as a Drug Delivery System.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, requiring the advancement of sophisticated treatment methods and accurate, non-invasive monitoring approaches. Superparamagnetic iron oxide@silver@chitosan (SPION@Ag@Cs) core-shell nanoparticles represent a potential platform for the targeted administration of sorafenib; yet real-time evaluation of therapy success at the molecular level continues to pose a difficulty. This study sought to assess the therapeutic efficacy of sorafenib-loaded SPION@Ag@Cs nanocomposites and to validate Fourier transform infrared (FTIR) spectroscopy as a label-free method for monitoring biochemical changes during HCC treatment. We employed FTIR spectroscopy alongside synchrotron-based FTIR micro-spectroscopy and imaging to examine treated HCC tissues. Quantification of macromolecular alterations in proteins and lipids was conducted within designated cytoplasmic areas and juxtaposed with negative and positive controls, employing bee venom (BV) as a reference natural product for HCC therapy. Spectral analysis identified specific biochemical indicators linked to disease development and therapy response. Positive control samples exhibited a substantial rise in protein β-sheet structures, a notable decrease in lipid content, and a drop in albumin-associated vibrational bands. After therapy with the SPION@Ag@Cs-sorafenib system, these spectral characteristics exhibited a quantifiable shift towards the healthy control condition. These variables particular macromolecular signatures function as sensitive biomarkers for detecting pathological conditions and monitoring therapeutic results. This study emphasizes the dual capability of SPION@Ag@Cs as an efficient nanocarrier for sorafenib and FTIR micro-spectroscopy as a rapid, objective, and economical method for early liver cancer screening and real-time treatment assessment.
Indexed as
Identifiers
42185728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.